First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)

Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30fdf5599db64195b591b2c71f3f2250
record_format	dspace
spelling	oai:doaj.org-article:30fdf5599db64195b591b2c71f3f22502021-12-05T12:14:47ZFirst-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)10.1038/s41598-021-02561-z2045-2322https://doaj.org/article/30fdf5599db64195b591b2c71f3f22502021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02561-zhttps://doaj.org/toc/2045-2322Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1–73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9–23.9) months. The median overall survival was not reached (95% confidence interval 24.6–not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis.Gaku YamamotoHajime AsahinaOsamu HonjoToshiyuki SumiAtsushi NakamuraKenichiro ItoHajime KikuchiFumihiro HommuraRyoichi HondaKeiki YokooYuka FujitaSatoshi OizumiRyo MoritaYasuyuki IkezawaHisashi TanakaNozomu KimuraTakaaki SasakiNoriaki SukohTaichi TakashinaToshiyuki HaradaHirotoshi Dosaka-AkitaHiroshi Isobethe Hokkaido Lung Cancer Clinical Study Group TrialNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gaku Yamamoto Hajime Asahina Osamu Honjo Toshiyuki Sumi Atsushi Nakamura Kenichiro Ito Hajime Kikuchi Fumihiro Hommura Ryoichi Honda Keiki Yokoo Yuka Fujita Satoshi Oizumi Ryo Morita Yasuyuki Ikezawa Hisashi Tanaka Nozomu Kimura Takaaki Sasaki Noriaki Sukoh Taichi Takashina Toshiyuki Harada Hirotoshi Dosaka-Akita Hiroshi Isobe the Hokkaido Lung Cancer Clinical Study Group Trial First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
description	Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1–73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9–23.9) months. The median overall survival was not reached (95% confidence interval 24.6–not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis.
format	article
author	Gaku Yamamoto Hajime Asahina Osamu Honjo Toshiyuki Sumi Atsushi Nakamura Kenichiro Ito Hajime Kikuchi Fumihiro Hommura Ryoichi Honda Keiki Yokoo Yuka Fujita Satoshi Oizumi Ryo Morita Yasuyuki Ikezawa Hisashi Tanaka Nozomu Kimura Takaaki Sasaki Noriaki Sukoh Taichi Takashina Toshiyuki Harada Hirotoshi Dosaka-Akita Hiroshi Isobe the Hokkaido Lung Cancer Clinical Study Group Trial
author_facet	Gaku Yamamoto Hajime Asahina Osamu Honjo Toshiyuki Sumi Atsushi Nakamura Kenichiro Ito Hajime Kikuchi Fumihiro Hommura Ryoichi Honda Keiki Yokoo Yuka Fujita Satoshi Oizumi Ryo Morita Yasuyuki Ikezawa Hisashi Tanaka Nozomu Kimura Takaaki Sasaki Noriaki Sukoh Taichi Takashina Toshiyuki Harada Hirotoshi Dosaka-Akita Hiroshi Isobe the Hokkaido Lung Cancer Clinical Study Group Trial
author_sort	Gaku Yamamoto
title	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
title_short	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
title_full	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
title_fullStr	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
title_full_unstemmed	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
title_sort	first-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (hot2002)
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
work_keys_str_mv	AT gakuyamamoto firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT hajimeasahina firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT osamuhonjo firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT toshiyukisumi firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT atsushinakamura firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT kenichiroito firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT hajimekikuchi firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT fumihirohommura firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT ryoichihonda firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT keikiyokoo firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT yukafujita firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT satoshioizumi firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT ryomorita firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT yasuyukiikezawa firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT hisashitanaka firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT nozomukimura firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT takaakisasaki firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT noriakisukoh firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT taichitakashina firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT toshiyukiharada firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT hirotoshidosakaakita firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT hiroshiisobe firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002 AT thehokkaidolungcancerclinicalstudygrouptrial firstlineosimertinibinelderlypatientswithepidermalgrowthfactorreceptormutatedadvancednonsmallcelllungcanceraretrospectivemulticenterstudyhot2002
_version_	1718372124705423360

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)

Ejemplares similares